Entries by

,

Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Authors Carolina Chaves, MD, Paulo Cesar T Bittencourt, MD, MSc, Andreia Pelegrini, PhD Published in Pain Medicine October 2020 Abstract Objective To determine the benefit of a tetrahydrocannabinol (THC)-rich cannabis oil on symptoms and quality of life of fibromyalgia patients. Methods A double-blind, randomized, placebo-controlled clinical trial was conducted for eight weeks to determine the…

Safety Considerations in Cannabinoid-Based Medicine

Authors Joshua Aviram, Gil M. Lewitus, Yelena Vysotski, Anton Uribayev, Shiri Procaccia, Idan Cohen, Anca Leibovici, Mahmud Abo-Amna, Luiza Akria, Dmitry Goncharov, Neomi Mativ, Avia Kauffman, Ayelet Shai, Or Hazan, Gil Bar-Sela and David Meiri Published in International Journal of General Medicine December 2020 Abstract Cannabinoids are a diverse class of chemical compounds that are…

,

Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Effects among Palliative Cancer Patients

Authors Joshua Aviram, Gil M. Lewitus, Yelena Vysotski, Anton Uribayev, Shiri Procaccia, Idan Cohen, Anca Leibovici, Mahmud Abo-Amna, Luiza Akria, Dmitry Goncharov, Neomi Mativ, Avia Kauffman, Ayelet Shai, Or Hazan, Gil Bar-Sela and David Meiri Published in Pharmaceuticals November 2020 Abstract In the last decade the use of medical cannabis (MC) for palliative cancer treatment…

,

Cannabidiol A Race To Relief

Authors: Nishi Whiteley and Ethan Russo, MD Published in HerbalGram 2020 Introduction Few chemical compounds have enjoyed such a rapid ascent to market acceptance and consumer popularity as CBD. According to BDS Analytics, the US hemp-derived CBD market is projected to grow to $20 billion by 2024.1 CBD was the top-selling herbal dietary supplement in…

,

Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

Authors: Serena Silvestro, Giovanni Schepici, Placido Bramanti, and Emanuela Mazzon Published in Molecules November 2020 Abstract The Cannabis sativa plant contains more than 120 cannabinoids. With the exceptions of ∆9-Cannabidiol (CBD) is a non-psychoactive phytocannabinoid known for its beneficial effects including antioxidant and anti-inflammatory properties. Moreover, CBD is a compound with antidepressant, anxiolytic, anticonvulsant and…

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

Authors: Ayat Zagzoog, Kawthar A. Mohamed, Hye Ji J. Kim, Eunhyun D. Kim, Connor S. Frank, Tallan Black, Pramodkumar D. Jadhav, Larry A. Holbrook & Robert B. Laprairie Published in Scientific Reports November 2020 Abstract The Cannabis sativa plant contains more than 120 cannabinoids. With the exceptions of ∆9-tetrahydrocannabinol (∆9-THC) and cannabidiol (CBD), comparatively little…

Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019

Authors: Prakash Nagarkatti, Kathryn Miranda and Mitzi Nagarkatti Published in Frontiers in Pharmacology November 2020 Abstract Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2. A significant proportion of COVID-19 patients develop Acute Respiratory Distress Syndrome (ARDS) resulting from hyperactivation of the immune system and…

,

Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota’s Medical Cannabis Program

Authors: Susan P Anderson, Dylan M Zylla, Deepa M McGriff, Tom J Arneson Published in Journal of Oncology Practice April 2019 Abstract Purpose: Minnesota’s medical cannabis program is unique, in that it routinely collects patient-reported scores on symptoms. This article focuses on changes in symptom severity reported by patients with cancer during their first 4 months…

,

Oncology Clinicians and the Minnesota Medical Cannabis Program: A Survey on Medical Cannabis Practice Patterns, Barriers to Enrollment, and Educational Needs

Authors: Dylan Zylla, Grant Steele , Justin Eklund, Jeanne Mettner, Tom Arneson Published in Cannabis and cannabinoid research October 2018 Abstract Background:Medical cannabis has been available in the State of Minnesota since July 2015 through the Minnesota Medical Cannabis Program (MMCP). Objectives: Our study aimed to delineate oncology providers’ views on medical cannabis, identify barriers…

, ,

Cannabinoids in Urology. Which Benign Conditions Might They Be Appropriate to Treat: A Systematic Review

Authors: Brian Robert Peter Birch, Charlie Taylor Published in Urology November 2020 Abstract There is growing evidence suggesting cannabinoids may provide suitable alternatives to conventional treatments in an increasing number of clinical settings. This review evaluates how cannabinoids are used to treat certain benign urologicalpathologies and to clarify the clinical value of this data. This…